Correction to: Psychometric Validation of the Autism Impact Measure (AIM) / R. HOUGHTON in Journal of Autism and Developmental Disorders, 49-6 (June 2019)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 49-6 (June 2019) . - p.2571 Titre : Correction to: Psychometric Validation of the Autism Impact Measure (AIM) Type de document : Texte imprimé et/ou numérique Auteurs : R. HOUGHTON, Auteur ; B. MONZ, Auteur ; K. LAW, Auteur ; G. LOSS, Auteur ; S. LE SCOUILLER, Auteur ; F. DE VRIES, Auteur ; T. WILLGOSS, Auteur Article en page(s) : p.2571 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : The article Psychometric Validation of the Autism Impact Measure (AIM), written by Richard Houghton, Brigitta Monz, Kiely Law, Georg Loss, Stephanie Le Scouiller, Frank de Vries and Tom Willgoss was originally published electronically on the publisher's internet portal (currently SpringerLink) on 09 April 2019 without open access.With the author(s)' decision to opt for Open Choice the copyright of the article changed on May 2019 to (c) The Author(s) 2019 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. En ligne : https://dx.doi.org/10.1007/s10803-019-04076-z Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=400 [article] Correction to: Psychometric Validation of the Autism Impact Measure (AIM) [Texte imprimé et/ou numérique] / R. HOUGHTON, Auteur ; B. MONZ, Auteur ; K. LAW, Auteur ; G. LOSS, Auteur ; S. LE SCOUILLER, Auteur ; F. DE VRIES, Auteur ; T. WILLGOSS, Auteur . - p.2571. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 49-6 (June 2019) . - p.2571 Index. décimale : PER Périodiques Résumé : The article Psychometric Validation of the Autism Impact Measure (AIM), written by Richard Houghton, Brigitta Monz, Kiely Law, Georg Loss, Stephanie Le Scouiller, Frank de Vries and Tom Willgoss was originally published electronically on the publisher's internet portal (currently SpringerLink) on 09 April 2019 without open access.With the author(s)' decision to opt for Open Choice the copyright of the article changed on May 2019 to (c) The Author(s) 2019 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. En ligne : https://dx.doi.org/10.1007/s10803-019-04076-z Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=400

Psychometric Validation of the Autism Impact Measure (AIM) / R. HOUGHTON in Journal of Autism and Developmental Disorders, 49-6 (June 2019)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 49-6 (June 2019) . - p.2559-2570 Titre : Psychometric Validation of the Autism Impact Measure (AIM) Type de document : Texte imprimé et/ou numérique Auteurs : R. HOUGHTON, Auteur ; B. MONZ, Auteur ; K. LAW, Auteur ; G. LOSS, Auteur ; S. LE SCOUILLER, Auteur ; F. DE VRIES, Auteur ; T. WILLGOSS, Auteur Article en page(s) : p.2559-2570 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Outcome  Psychometric validation  Symptoms  Treatment Index. décimale : PER Périodiques Résumé : The Autism impact measure (AIM) is a caregiver-reported questionnaire assessing autism symptom frequency and impact in children, previously shown to have good test-retest reliability, convergent validity and structural validity. This study extended previous work by exploring the AIM's ability to discriminate between 'known-groups' of children, and estimating thresholds for clinically important responses. Data were collected online and electronically on computer and mobile devices; hence, it was also possible to confirm other psychometric properties of the AIM in this format. This study provides confirmatory and additional psychometric validation of the AIM. The AIM offers a valid, quick and inexpensive method for caregivers to report core symptoms of autism spectrum disorder (ASD) including communication deficits, difficulties with social interactions and repetitive behaviors. En ligne : https://dx.doi.org/10.1007/s10803-019-04011-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=400 [article] Psychometric Validation of the Autism Impact Measure (AIM) [Texte imprimé et/ou numérique] / R. HOUGHTON, Auteur ; B. MONZ, Auteur ; K. LAW, Auteur ; G. LOSS, Auteur ; S. LE SCOUILLER, Auteur ; F. DE VRIES, Auteur ; T. WILLGOSS, Auteur . - p.2559-2570. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 49-6 (June 2019) . - p.2559-2570 Mots-clés : Autism spectrum disorder  Outcome  Psychometric validation  Symptoms  Treatment Index. décimale : PER Périodiques Résumé : The Autism impact measure (AIM) is a caregiver-reported questionnaire assessing autism symptom frequency and impact in children, previously shown to have good test-retest reliability, convergent validity and structural validity. This study extended previous work by exploring the AIM's ability to discriminate between 'known-groups' of children, and estimating thresholds for clinically important responses. Data were collected online and electronically on computer and mobile devices; hence, it was also possible to confirm other psychometric properties of the AIM in this format. This study provides confirmatory and additional psychometric validation of the AIM. The AIM offers a valid, quick and inexpensive method for caregivers to report core symptoms of autism spectrum disorder (ASD) including communication deficits, difficulties with social interactions and repetitive behaviors. En ligne : https://dx.doi.org/10.1007/s10803-019-04011-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=400

Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders / R. HOUGHTON in Autism Research, 14-8 (August 2021)  

Public ISBD [article]  inAutism Research > 14-8 (August 2021) . - p.1800-1814 Titre : Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders Type de document : Texte imprimé et/ou numérique Auteurs : R. HOUGHTON, Auteur ; J. VAN DEN BERGH, Auteur ; K. LAW, Auteur ; Y. LIU, Auteur ; F. DE VRIES, Auteur Article en page(s) : p.1800-1814 Langues : Anglais (eng) Mots-clés : Adolescent  Antipsychotic Agents/adverse effects  Aripiprazole/adverse effects  Autism Spectrum Disorder/complications/drug therapy/epidemiology  Child  Cohort Studies  Female  Fractures, Bone/drug therapy/epidemiology  Humans  Male  Retrospective Studies  Risperidone/adverse effects  United States/epidemiology  antipsychotics  aripiprazole  autism spectrum disorder  fractures  risperidone Index. décimale : PER Périodiques Résumé : Risperidone and aripiprazole, commonly used antipsychotics in children with autism spectrum disorder (ASD), have previously been associated with elevated fracture risk in other populations. The aim of this study was to evaluate and compare the risk of fracture among children with ASD using risperidone or aripiprazole. This was a retrospective, propensity-score matched cohort study, set between January 2013 and December 2018. We used the MarketScan Medicaid insurance data, which covers multiple states of the United States. We included ASD children aged 2-18?years, who were new users of aripiprazole or risperidone and with no prior history of antipsychotic use or fractures. The main exposure was the continued use of aripiprazole or risperidone. The incidence rates of any fracture during follow-up were evaluated, and the risk between aripiprazole and risperidone was compared via Cox-proportional hazard models. Results were stratified by age, sex, duration of exposure and fracture site. In total, 3312 patients (78% male; mean [SD] age 11.0 [3.7] years) were identified for each cohort. Over the full duration of follow-up, fracture incidence rates per 1000 patient-years were 23.2 for risperidone and 38.4 for aripiprazole (hazard ratio and 95% confidence interval: 0.60 [0.44-0.83]). Risks were similar between cohorts throughout the first 180?days on treatment, but significantly higher in the aripiprazole group thereafter. Extremity fractures drove most of the increased risk, with the biggest differences in lower leg and ankle fractures. Differences widened for children aged 10?years or younger (HR [95% CI]: 0.47 [0.30-0.74]). In conclusion, compared to aripiprazole, risperidone was associated with 40% lower risk of fracture. Further analysis on the mechanism and long-term bone health of antipsychotic-treated children with ASD is warranted. LAY SUMMARY: We compared the risk of bone fractures among 6624 children with autism spectrum disorder (ASD), half of whom used risperidone and half of whom used aripiprazole. Taking other factors into account, risks were similar between the two groups throughout the first 180?days on treatment, but significantly higher in the aripiprazole group thereafter. The biggest differences were in lower leg and ankle fractures. Overall, compared with aripiprazole, risperidone was associated with 40% lower risk of fracture. En ligne : http://dx.doi.org/10.1002/aur.2541 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449 [article] Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders [Texte imprimé et/ou numérique] / R. HOUGHTON, Auteur ; J. VAN DEN BERGH, Auteur ; K. LAW, Auteur ; Y. LIU, Auteur ; F. DE VRIES, Auteur . - p.1800-1814. Langues : Anglais (eng) in Autism Research > 14-8 (August 2021) . - p.1800-1814 Mots-clés : Adolescent  Antipsychotic Agents/adverse effects  Aripiprazole/adverse effects  Autism Spectrum Disorder/complications/drug therapy/epidemiology  Child  Cohort Studies  Female  Fractures, Bone/drug therapy/epidemiology  Humans  Male  Retrospective Studies  Risperidone/adverse effects  United States/epidemiology  antipsychotics  aripiprazole  autism spectrum disorder  fractures  risperidone Index. décimale : PER Périodiques Résumé : Risperidone and aripiprazole, commonly used antipsychotics in children with autism spectrum disorder (ASD), have previously been associated with elevated fracture risk in other populations. The aim of this study was to evaluate and compare the risk of fracture among children with ASD using risperidone or aripiprazole. This was a retrospective, propensity-score matched cohort study, set between January 2013 and December 2018. We used the MarketScan Medicaid insurance data, which covers multiple states of the United States. We included ASD children aged 2-18?years, who were new users of aripiprazole or risperidone and with no prior history of antipsychotic use or fractures. The main exposure was the continued use of aripiprazole or risperidone. The incidence rates of any fracture during follow-up were evaluated, and the risk between aripiprazole and risperidone was compared via Cox-proportional hazard models. Results were stratified by age, sex, duration of exposure and fracture site. In total, 3312 patients (78% male; mean [SD] age 11.0 [3.7] years) were identified for each cohort. Over the full duration of follow-up, fracture incidence rates per 1000 patient-years were 23.2 for risperidone and 38.4 for aripiprazole (hazard ratio and 95% confidence interval: 0.60 [0.44-0.83]). Risks were similar between cohorts throughout the first 180?days on treatment, but significantly higher in the aripiprazole group thereafter. Extremity fractures drove most of the increased risk, with the biggest differences in lower leg and ankle fractures. Differences widened for children aged 10?years or younger (HR [95% CI]: 0.47 [0.30-0.74]). In conclusion, compared to aripiprazole, risperidone was associated with 40% lower risk of fracture. Further analysis on the mechanism and long-term bone health of antipsychotic-treated children with ASD is warranted. LAY SUMMARY: We compared the risk of bone fractures among 6624 children with autism spectrum disorder (ASD), half of whom used risperidone and half of whom used aripiprazole. Taking other factors into account, risks were similar between the two groups throughout the first 180?days on treatment, but significantly higher in the aripiprazole group thereafter. The biggest differences were in lower leg and ankle fractures. Overall, compared with aripiprazole, risperidone was associated with 40% lower risk of fracture. En ligne : http://dx.doi.org/10.1002/aur.2541 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=449

---

1 (1 - 3 / 3)